Ayurvedic Drug For COVID-19: Dalmia Healthcare starts clinical trials of polyherbal combo Astha-15

As per the study, the drug acts as a bronchodilator, decongestant, anti-inflammatory, lung detoxifier and did not show any side-effects, it added

Published On 2020-06-07 04:15 GMT   |   Update On 2020-06-07 04:15 GMT
Advertisement

New Delhi: Dalmia Healthcare on Thursday said it has started clinical trials to evaluate the efficacy and safety of its polyherbal combination 'Astha-15' for treatment of COVID-19.

All regulatory guidelines will be followed to conduct the multi-centric, Phase III clinical trials, the Dalmia Group firm said in a statement.

"We are conducting human trials of our highly efficient ayurvedic composition which can potentially help in curing COVID-19 patients," Dalmia Group of Companies Chairman Sanjay Dalmia said.

Advertisement

The polyherbal combination by the company has previously undergone a randomised double-blind, placebo-controlled study on patients in a speciality government hospital in Chennai, the statement said.

As per the study, the drug acts as a bronchodilator, decongestant, anti-inflammatory, lung detoxifier and did not show any side-effects, it added.

Read also: Ayurvedic Drug 'Fifatrol' Finds Mention In Compendium To Tackle COVID-19

Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News